Nimble Therapeutics has entered into a strategic collaboration with Incyte, a pharmaceutical company, to discover first-in-class peptide therapies across various disease areas, the company announced recently. “This is an important…
OnLume has been awarded a $2 million grant from the U.S. National Institutes of Health’s National Cancer Institute to advance the development of its proprietary device for Fluorescence-Guided Surgery (FGS),…
SHINE Medical Technologies has closed an $80 million Series C financing round, the company announced recently. “This funding round will help SHINE’s continuing efforts to commercialize vital diagnostic and therapeutic…
The problem with current opioid use disorder (OUD) medication-assisted treatment is that in between doses, individuals are more likely to relapse because they must willingly choose to take their next…
Propeller Health announced today it will begin distributing in Japan through collaboration with Novartis by connecting Propeller’s digital health platform to two of Novartis’ medications. According to a release, Enerzair Breezhaler…
NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently….
OnLume announced recently that it is beginning a clinical trial for its fluorescence-guided surgery (FGS) imaging device, which will be combined with a novel nerve-targeting agent. The Phase I-II study, which…
Promega surpassed its environmental improvement goals set for the end of 2020 and achieved reductions in key sustainability metrics, according to its newly released Corporate Responsibility Report, the company announced…
Promega’s Maxwell RNA Extraction System has been authorized for use in the CDC’s COVID-19 diagnostic testing protocol, the company announced today. The FDA granted the authorization on Monday. “This announcement…
Propeller Health will co-package the Propeller digital health platform with Novartis’ Enerzair Breezhaler, a recently approved medication developed to treat uncontrolled asthma, the company announced today. According to a release, the…
